Last reviewed · How we verify
Colistin/Polymyxin B + Sulbactam
Colistin and polymyxin B disrupt bacterial cell membranes while sulbactam inhibits bacterial β-lactamases, together providing broad-spectrum activity against multidrug-resistant gram-negative bacteria.
Colistin and polymyxin B disrupt bacterial cell membranes while sulbactam inhibits bacterial β-lactamases, together providing broad-spectrum activity against multidrug-resistant gram-negative bacteria. Used for Multidrug-resistant gram-negative bacterial infections (Acinetobacter baumannii, Pseudomonas aeruginosa), Hospital-acquired and ventilator-associated pneumonia caused by resistant organisms.
At a glance
| Generic name | Colistin/Polymyxin B + Sulbactam |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Polymyxin antibiotic + β-lactamase inhibitor combination |
| Target | Bacterial cell membrane (polymyxins); bacterial β-lactamases (sulbactam) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Colistin and polymyxin B are cationic cyclic peptides that bind to and disrupt the outer membrane of gram-negative bacteria, causing cell lysis and death. Sulbactam is a β-lactamase inhibitor that protects β-lactam antibiotics from enzymatic degradation and has intrinsic antibacterial activity. This combination targets multidrug-resistant organisms, particularly Acinetobacter baumannii and Pseudomonas aeruginosa.
Approved indications
- Multidrug-resistant gram-negative bacterial infections (Acinetobacter baumannii, Pseudomonas aeruginosa)
- Hospital-acquired and ventilator-associated pneumonia caused by resistant organisms
Common side effects
- Nephrotoxicity
- Neurotoxicity (paresthesias, dizziness)
- Injection site reactions
- Fever
Key clinical trials
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colistin/Polymyxin B + Sulbactam CI brief — competitive landscape report
- Colistin/Polymyxin B + Sulbactam updates RSS · CI watch RSS
- National University of Singapore portfolio CI